ArticleBreast cancer (Tokyo, Japan)2026
Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2-metastatic breast cancer.
Tuğba Önder et al.PubMed ↗Publisher ↗
No numbers read from the abstract.